Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03482648 · ClinicalTrials.gov registry record · Phase 1
First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers
A Phase 1 study, sponsored by Bridge Biotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT03482648: Completed Phase 1 study, sponsored by Bridge Biotherapeutics.
NCT03482648 is a Phase 1 study that has completed, run by Bridge Biotherapeutics. The registered enrollment target is 80 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03482648, a Phase 1 study, has completed, sponsored by Bridge Biotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
This clinical trial is the first-in-human study of BBT-401-1S. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of BBT-401-1S in healthy adult subjects.
Primary Outcome
To assess the safety and tolerability of single and multiple ascending oral doses of BBT-401-1S in healthy adult subjects.
Interventions
- DRUG Placebo
- DRUG BBT-401-1S, Single dose
- DRUG BBT-401-1S, Multiple doses
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2018-03-20 |
| Est. Completion | 2018-10-03 |
| Phase | Phase 1 |
What the finished NCT03482648 record still lists
NCT03482648 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03482648 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03482648 about?
NCT03482648 is a clinical study titled "First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers". This clinical trial is the first-in-human study of BBT-401-1S. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of BBT-401-1S in healthy adult subjects.
What is the current status of trial NCT03482648?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2018-03-20. Estimated completion is 2018-10-03.
What interventions are being tested in trial NCT03482648?
The interventions under investigation include: Placebo (DRUG), BBT-401-1S, Single dose (DRUG), BBT-401-1S, Multiple doses (DRUG).
Who is sponsoring clinical trial NCT03482648?
This trial is sponsored by Bridge Biotherapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03482648's enrollment target sits among peer trials
80 672nd of 2000 higher than 1,305 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI